Vaxcyte, Inc. (NASDAQ:PCVX) Receives $106.25 Consensus Price Target from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $106.25.

A number of equities analysts have weighed in on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th.

Vaxcyte Trading Down 0.1%

NASDAQ:PCVX opened at $41.65 on Friday. The firm’s fifty day simple moving average is $38.09 and its 200 day simple moving average is $35.02. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $107.31. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of -8.61 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the prior year, the business posted ($0.83) earnings per share. On average, analysts predict that Vaxcyte will post -4.21 earnings per share for the current year.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of the business. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 40.3% in the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company’s stock worth $460,262,000 after acquiring an additional 3,499,959 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Vaxcyte by 44.4% in the 1st quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock valued at $242,303,000 after purchasing an additional 1,972,918 shares in the last quarter. Norges Bank purchased a new position in shares of Vaxcyte during the 2nd quarter valued at approximately $32,109,000. Westfield Capital Management Co. LP boosted its stake in shares of Vaxcyte by 42.4% during the 2nd quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock valued at $99,770,000 after buying an additional 913,761 shares during the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Vaxcyte during the second quarter worth approximately $26,318,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.